285984-25-0

Basic information

• Product Name: 5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylamine
• Synonyms: 1H-Pyrazol-5-aMine, 3-(1,1-diMethylethyl)-1-(4-Methylphenyl)-;5-tert-butyl-2-(4-Methylphenyl)pyrazol-3-aMine;[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]amine;5-tert-butyl-2-(4-methylphenyl)-3-pyrazolamine;STK234818;ZINC02527276;BUTTPARK 74\09-04;5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YLAMINE
• CAS NO: 285984-25-0
• Molecular Formula: C₁₄H₁₉N₃
• Molecular Weight: 229.32
• Product Categories: Chemical Synthesis;Heterocyclic Building Blocks;New Products for Chemical Synthesis;Pyrazoles;Heterocycles;Building Blocks;C12 to C37
• Mol File: 285984-25-0.mol

Chemical Properties

• Boiling Point: 368.271 °C at 760 mmHg
• Flash Point: 176.524 °C
• Appearance: /
• Density: 1.066 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.571
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 4.17±0.10(Predicted)
• CAS DataBase Reference: 5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylamine(285984-25-0)
• EPA Substance Registry System: 5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylamine(285984-25-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 285984-25-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylamine is utilized as a reagent in organic synthesis for its ability to participate in various chemical reactions, contributing to the formation of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylamine is employed as a research compound for its pharmacological activity. It is particularly noted for its potential as an anti-inflammatory and analgesic agent, making it a candidate for the development of new medications targeting pain and inflammation.
Used in Neurodegenerative Disease Treatment:
5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylamine is also studied for its potential application in the treatment of neurodegenerative diseases. Its capacity to modulate neurotransmission suggests that it could be instrumental in managing conditions associated with impaired neuronal communication.

InChI:InChI=1/C14H19N3/c1-10-5-7-11(8-6-10)17-13(15)9-12(16-17)14(2,3)4/h5-9H,15H2,1-4H3

Upstream product

• 59997-51-2 trimethylacetylacetonitrile 
• 539-44-6 N-4-methylphenylhydrazine 
• 35467-65-3 4-methylphenylhydrazine hydrochloride 
• 637-60-5 p-tolylhydrazine hydrochloride 

Downstream Products

• 925899-74-7 tert-butyl 4-(3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)phenylcarbamate 
• 925899-72-5 1-[4-(6-aminopurin-9-yl)phenyl]-3-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)urea 
• 848144-14-9 N-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 
• 1229649-67-5 tert-butyl 4-(2-(4-(3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)propyl)pyridin-2-ylcarbamate 
• 1229607-19-5 (R)-N-(4-(4-(3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)pyridin-2-yl)-3-(dimethylamino)pyrrolidine-1-carboxamide 
• 1229649-74-4 tert-butyl 4-(1-(4-(3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)propan-2-yl)pyridin-2-ylcarbamate 
• 1229649-81-3 tert-butyl 4-(1-(4-(3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-yl oxy)-2-methylpropan-2-yl)pyridin-2-ylcarbamate 
• 1229649-45-9 N-(4-((4-(3-(3-tert-butyl-1-(4-(hydroxymethyl)phenyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)methyl)pyridin-2-yl)-2-methoxyacetamide 
• 1220627-13-3 di-tert-butyl 4-((4-(3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido) naphthalen-1-yloxy)methyl)pyridin-3-yliminodicarbonate 
• 1220627-18-8 tert-butyl (4-(2-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)pyridin-2-yl)carbamate 
• 1451069-25-2 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((3-hydroxyphenyl) amino)pyrimidin-4-yl)oxy)naphthalen-1-yl)urea 
• 1379397-83-7 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-(phenylamino)pyrimidin-4-yl)oxy)naphthalen-1-yl)urea 
• 1255040-37-9 N-((3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)methyl)-2-(3-fluoro-4-(methylsulphonamido)phenyl)propanamide 
• 1352798-73-2 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((8-oxo-8,9-dihydro-7H-purin-6-yl)oxy)naphthalen-1-yl)urea 

Relevant articles and documents

MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF

Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutica

Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists

A series of 1-substituted 3-(t-butyl/trifluoromethyl)pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides were investigated for hTRPV1 antagonism. The structure activity relationship indicated that the 3-chlorophenyl group at the 1-position of pyrazole was the optimized hydrophobic group for antagonistic potency and the activity was stereospecific to the S-configuration, providing exceptionally potent antagonists 13S and 16S with Ki(CAP) = 0.1 nM. Particularly significant, 13S exhibited antagonism selective for capsaicin and NADA and not for low pH or elevated temperature. Both compounds also proved to be very potent antagonists for rTRPV1, blocking in vivo the hypothermic action of capsaicin, consistent with their in vitro mechanism. The docking study of compounds 13S and 16S in our hTRPV1 homology model indicated that the binding modes differed somewhat, with that of 13S more closely resembling that of GRT12360.

Substituted benzo pyrazole diaryl urea compound, its preparation method and medical use thereof (by machine translation)

The invention substituted benzo pyrazole diaryl urea compound, its preparation method and medical use thereof relates to a compound of formula I, or an isomer, a pharmaceutically acceptable salt and solvates; the invention also relates to the general formula I compound or its isomer, pharmaceutically acceptable salt and solvates, and a pharmaceutically acceptable carrier, excipient or diluent composition; the invention also relates to the compounds of the formula I, or an isomer, a pharmaceutically acceptable salt and solvates, used for overcoming the inflammation, inflammation-related diseases, tumor and asphyxiating gas or irritant gas caused by the use of acute lung injury; in particular with the P38 MAPK pathway-related diseases or symptoms in use. (by machine translation)

Novel diaryl urea compounds, and preparation method and medical applications thereof

The invention relates to compounds represented by the formula (I), and isomers, pharmaceutically acceptable salts, and solvates thereof. The invention further relates to a composition, which comprises abovementioned compounds, isomers, salts, and solvates, and a pharmaceutically acceptable carrier, excipient, or diluent; and applications of abovementioned compounds, isomers, salts, and solvates in treating diseases and symptoms of acute lung injury caused by inflammation, diseases related with inflammation, tumor, suffocating gas, and irritant gas, especially an application of treating P38MAPK related diseases and symptoms.

Substituted benzothiazole diaryl urea compounds, and preparation method and medical application thereof

The invention relates to compounds as shown in a general formula I which is described in the specification, or isomers, medicinal salts and solvates thereof. The invention also relates to a composition containing the compounds as shown in the general formula I or the isomers, medicinal salts and solvates thereof, and a pharmaceutically acceptable carrier, an excipient or a diluent. The invention also relates to application of the compounds as shown in the general formula I or the isomers, medicinal salts and solvates thereof to treatment of inflammations, inflammation-related diseases, tumors and acute lung injury or symptoms caused by suffocating gas or irritant gas, especially to diseases or symptoms related to a P38 MAPK pathway.

Synthesis and p38 inhibitory activity of some novel substituted N,N′-diarylurea derivatives

We have identified a novel series of substituted N,N′-diarylurea p38α inhibitors. The inhibitory activity of the target compounds against the enzyme p38α, MAPKAPK2 in BHK cells, TNF-α release in LPS-stimulated THP-1 cells and p38α binding experiments were

Biophysical investigation and conformational analysis of p38α kinase inhibitor doramapimod and its analogues

Doramapimod (BIRB 796) is a potent inhibitor of p38α mitogen-activated protein kinase. It contains an aryl-pyrazole scaffold as a pharmacophore critical for binding. The aryl-pyrazole scaffold is not planar and adopts an out-of-plane conformation, which is described by the torsion angle θ. In this letter, we report the chemical synthesis and biophysical characterization of different analogues of doramapimod (3-12) exhibiting distinctly different aryl-pyrazole torsion angle θ values. The torsion angle θ values of the synthesized analogues (3-6) were determined by crystal structural analysis and the binding affinities to p38α kinase investigated by microscale thermophoresis. Our results unveil a clear correlation between kinase binding and the torsion angle θ of tested doramapimod analogues, highlighting the importance of inhibitor conformation for protein binding.

Design, synthesis and biological evaluation of novel substituted N,N′-diaryl ureas as potent p38 inhibitors

A novel series of substituted N,N′-diaryl ureas that act as p38α inhibitors have been designed and synthesized based on two key residues (Gly110 and Thr106) that are different in p38α MAPK than in other kinases. Preliminary biological evaluation indicated

INHIBITOR OF p38 MAP KINASE

A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.

ANTI-MUCUS DRUGS AND USES THEREFOR

Disclosed are methods of identifying, generating and synthesizing compounds that inhibit MAPK13 activity. In various embodiments, compounds, salts thereof and prodrugs thereof of the present teachings can be useful for the treatment of diseases and disord